AURA phase-I trial indicated that Osimertinib had certain efficacy in T790M mutation-negative NSCLC patients with EGFR-TKI resistance, the subgroup at the dosage of 120mg/d demonstrating a 30% response rate. This evidence concerns the gene EGFR and non-small cell lung carcinoma.